HC Wainwright restated their buy rating on shares of Kronos Bio (NASDAQ:KRON – Get Rating) in a research note issued to investors on Monday, Benzinga reports. The firm currently has a $10.00 price target on the stock. HC Wainwright also issued estimates for Kronos Bio’s Q1 2023 earnings at ($0.18) EPS, Q2 2023 earnings at […]